Karyopharm Therapeutics (KPTI) Stock Forecast & Price Target $0.34 -0.05 (-11.56%) As of 02:34 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings Karyopharm Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 7 Analyst RatingsSell1Hold2Buy4 Based on 7 Wall Street analysts who have issued ratings for Karyopharm Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a sell rating, 2 have given a hold rating, 3 have given a buy rating, and 1 has given a strong buy rating for KPTI. Consensus Price Target $11.503,233.33% Upside According to the 7 analysts' twelve-month price targets for Karyopharm Therapeutics, the average price target is $11.50. The highest price target for KPTI is $28.00, while the lowest price target for KPTI is $3.00. The average price target represents a forecasted upside of 3,233.33% from the current price of $0.35. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for KPTI and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Karyopharm Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KPTI Analyst Ratings Over TimeTypeCurrent Forecast10/19/25 to 10/19/261 Month Ago9/19/25 to 9/19/263 Months Ago7/21/25 to 7/21/261 Year Ago10/19/24 to 10/19/25Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)Buy3 Buy rating(s)3 Buy rating(s)5 Buy rating(s)5 Buy rating(s)Hold2 Hold rating(s)2 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$11.50$11.50$17.17$18.20Forecasted Upside3,233.33% Upside511.70% Upside118.41% Upside206.91% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy KPTI Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History KPTI Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Karyopharm Therapeutics Stock vs. The CompetitionTypeKaryopharm TherapeuticsHealthcare CompaniesBroader MarketConsensus Rating Score 2.57 2.32 2.53Consensus RatingModerate BuyHoldModerate BuyPredicted Upside2,847.96% Upside1,213.72% Upside18.01% UpsideNews Sentiment RatingNeutral NewsSee Recent KPTI NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/19/2024 - 10/19/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails9/24/2026 Weiss Ratings3 of 5 stars DowngradeSell (D-) ➝ Sell (E+)7/31/2026 HC Wainwright4 of 5 starsRobert Burns5 of 5 starsDowngradeBuy ➝ Negative7/31/2026 Piper Sandler2 of 5 starsEdward Tenthoff4 of 5 starsLower TargetOverweight$7.00+210.56%7/31/2026 Robert W. BairdSubscribe to MarketBeat All Access to unlock brokerage rankingsMichael UlzSubscribe to MarketBeat All Access to unlock analyst rankingsDowngradeOutperform ➝ Neutral$3.00-57.20%7/21/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access to unlock brokerage rankings Reiterated RatingOutperform$16.00+98.76%6/9/2026 Cantor FitzgeraldSubscribe to MarketBeat All Access to unlock brokerage rankings Reiterated RatingOverweight3/10/2026 Rodman & RenshawSubscribe to MarketBeat All Access to unlock brokerage rankingsMichael KingSubscribe to MarketBeat All Access to unlock analyst rankingsUpgradeStrong-Buy12/17/2025 The Goldman Sachs GroupSubscribe to MarketBeat All Access to unlock brokerage rankings Set Target$12.00+84.19%5/13/2025 BarclaysSubscribe to MarketBeat All Access to unlock brokerage rankingsPeter LawsonSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$5.00 ➝ $10.00+88.68%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:35 PM ET. KPTI Forecast - Frequently Asked Questions What is Karyopharm Therapeutics' forecast for 2026? According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Karyopharm Therapeutics is $11.50, with a high forecast of $28.00 and a low forecast of $3.00. Should I buy or sell Karyopharm Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There is currently 1 sell rating, 2 hold ratings, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KPTI shares. Does Karyopharm Therapeutics's stock price have much upside? According to analysts, Karyopharm Therapeutics's stock has a predicted upside of 3,233.33% based on their 12-month stock forecasts. Has Karyopharm Therapeutics been upgraded or downgraded by Wall Street analysts recently? Over the previous 90 days, Karyopharm Therapeutics's stock had 5 downgrades and 2 upgrades by analysts. What analysts cover Karyopharm Therapeutics? Karyopharm Therapeutics has been rated by research analysts at HC Wainwright, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Karyopharm Therapeutics more than its competitors? Analysts like Karyopharm Therapeutics more than other "healthcare" companies. The consensus rating for Karyopharm Therapeutics is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how KPTI compares to other companies. Stock Forecasts and Research Tools Related Companies Athira Pharma Stock Forecast Clene Stock Forecast CervoMed Stock Forecast Dogwood Therapeutics Stock Forecast RYTHM Stock Forecast Grace Therapeutics Stock Forecast Veru Stock Forecast SCYNEXIS Stock Forecast Cassava Sciences Stock Forecast Incannex Healthcare Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Karyopharm Therapeutics RecommendationsWeiss RatingsWall Street ZenHC WainwrightPiper SandlerRobert W. BairdRoyal Bank Of CanadaCantor FitzgeraldRodman & RenshawThe Goldman Sachs Group MarketBeat monitors more than a dozen sources for Karyopharm Therapeutics analyst ratings, with the most recent rating issued on 9/24/2026. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
